Introduction: Information on the long-term effects of psychogenic nonepileptic seizures (PNES) is limited. We therefore reassessed 22 patients 4-6 years after the initial diagnosis of PNES in a tertiary referral epilepsy center. The diagnosis was confirmed using clinical description and additional electroencephalogram investigations in 1998, 1999, and 2000. Patients with epilepsy and PNES as comorbid symptoms were not included. Reassessments were aimed at seizure reduction and possible psychogenic factors.
Methods: Three psychological tests were used at baseline at the time of diagnosis and repeated at end point. These three tests assessed different "levels" of psychological function [i.e., complaints (The Symptoms Check List Revised), coping strategy (The Dissociation Questionnaire), and personality factors/psychopathology Nederlandse Verkorte MMPI].
Results: Twenty-two patients were included. Seizure frequency showed statistically significant reduction. At the time of diagnosis, none of the patients was seizure-free or had only yearly seizures, whereas at end point, 7 of 22 patients were completely in remission and 3 patients had only occasional seizures. The number of patients with daily seizures dropped from nine to two. It has not been fully clarified which factors caused this improvement, but the common denominators are that a definitive expert diagnosis in a tertiary center was made and all possible efforts were made to inform the patient in a respectful manner about the diagnosis. In addition to seizure reduction, there was improvement on different levels of psychological function, showing reduction in psychological distress, reduction in dissociative features such as amnesia, increase in self-control, reduction in feelings of dissatisfaction and passive avoidant behavior, and a more active attitude towards social contact.
Conclusion: In the long term, the patients with PNES who were included in our study have more self-control and approach social contact with a more self-confident attitude. This does not necessary reflect a causal relationship with the observed seizure reduction. Nonetheless, it is noteworthy that, post aut propter, the eradication of a symptom (i.e., seizures) with social consequences is followed by or is associated with a more confident social attitude. This opens possibilities for treatment strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpsychores.2006.11.015 | DOI Listing |
Epilepsia
March 2025
University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, California, USA.
Objective: We analyzed the long-term safety and effectiveness of fenfluramine (FFA) in patients with Dravet syndrome (DS) in an open-label extension (OLE) study after participating in randomized controlled trials (RCTs) or commencing FFA de novo as adults.
Methods: Patients with DS who participated in one of three RCTs or were 19 to 35 years of age and started FFA de novo were included. Key endpoints were: incidence of treatment-emergent adverse events (TEAEs) in the safety population, and median percentage change in monthly convulsive seizure frequency (MCSF) from the RCT baseline to end of study (EOS) in the modified intent-to-treat (mITT) population.
Background: Glioma are infiltrative primary brain tumours, which despite treatment, lead to a substantial reduction in life expectancy. Seizures are a common symptom of glioma, and have a serious impact on patient health related quality of life (HRQoL).
Objective: The study aimed to estimate health state utility values for different types of seizures related to glioma, a serious type of brain tumour.
Neurol Ther
March 2025
Department of Human Neurosciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Introduction: Subjects with intellectual disability are usually excluded from clinical trials and there is limited evidence-based guidance for the choice of antiseizure medications in this vulnerable population. The study explored the effectiveness of brivaracetam (BRV) in people with epilepsy and intellectual disability.
Methods: BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST) was a 12-month retrospective, multicenter study including adults prescribed adjunctive BRV.
Methods Mol Biol
March 2025
Univ Lyon, Université Claude Bernard Lyon 1, INSERM, Stem Cell and Brain Research Institute U1208, Bron, France.
Lineage reprogramming of glial cells into induced neurons (iNs) has emerged as an innovative strategy to replace neurons lost due to injury or neurological diseases. Here, we describe a step-by-step protocol to induce in vivo conversion of reactive glial cells, proliferating within the injured hippocampus, into mature and functional GABAergic iNs through retrovirus-mediated expression of two neurogenic fate determinants (Ascl1 and Dlx2). We have previously applied this method to study the integration and functional impact of GABAergic iNs in epileptic mice (Lentini et al.
View Article and Find Full Text PDFNeuropsychiatr Dis Treat
March 2025
Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Objective: The study aims to compare the clinical efficacy and cognitive side effect of magnetic seizure therapy (MST) and modified electroconvulsive therapy (MECT) on clozapine resistant schizophrenia (CRS).
Methods: Sixteen patients with CRS were enrolled in this randomized, parallel-group, controlled clinical trial. Patients were randomly allocated to receive 10 sessions of add-on MST or MECT over 4 weeks (1:1 ratio) and continued clozapine therapy during the study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!